Compare RDNT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDNT | IMVT |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 5.0B |
| IPO Year | 1996 | 2019 |
| Metric | RDNT | IMVT |
|---|---|---|
| Price | $54.83 | $24.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $86.00 | $30.78 |
| AVG Volume (30 Days) | 799.9K | ★ 1.1M |
| Earning Date | 05-11-2026 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,616,630,000.00 | N/A |
| Revenue This Year | $22.78 | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.05 | N/A |
| 52 Week Low | $45.00 | $12.72 |
| 52 Week High | $85.84 | $29.25 |
| Indicator | RDNT | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 31.26 | 46.81 |
| Support Level | $54.50 | $22.00 |
| Resistance Level | $60.05 | $24.63 |
| Average True Range (ATR) | 2.53 | 1.25 |
| MACD | -0.44 | 0.08 |
| Stochastic Oscillator | 17.38 | 55.61 |
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.